News
Hims & Hers stock plunges after Novo Nordisk ends Wegovy direct sales deal
Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth platform.
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...
Daily Voice on MSN14h
Plainsboro-Based Wegovy Provider Ends Hims & Hers Deal Over Knockoff Weight-Loss Drug SalesNovo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback